BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taccetti G, Francalanci M, Pizzamiglio G, Messore B, Carnovale V, Cimino G, Cipolli M. Cystic Fibrosis: Recent Insights into Inhaled Antibiotic Treatment and Future Perspectives. Antibiotics (Basel) 2021;10:338. [PMID: 33810116 DOI: 10.3390/antibiotics10030338] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Maisetta G, Piras AM, Motta V, Braccini S, Mazzantini D, Chiellini F, Zambito Y, Esin S, Batoni G. Antivirulence Properties of a Low-Molecular-Weight Quaternized Chitosan Derivative against Pseudomonas aeruginosa. Microorganisms 2021;9:912. [PMID: 33923269 DOI: 10.3390/microorganisms9050912] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
2 Iafisco M, Carella F, Esposti LD, Adamiano A, Catalucci D, Modica J, Bragonzi A, Vitali A, Torelli R, Sanguinetti M, Bugli F. Biocompatible antimicrobial colistin loaded calcium phosphate nanoparticles for the counteraction of biofilm formation in cystic fibrosis related infections. Journal of Inorganic Biochemistry 2022. [DOI: 10.1016/j.jinorgbio.2022.111751] [Reference Citation Analysis]
3 Schwarz C, Taccetti G, Burgel P, Mulrennan S. Tobramycin safety and efficacy review article. Respiratory Medicine 2022. [DOI: 10.1016/j.rmed.2022.106778] [Reference Citation Analysis]
4 Glen KA, Lamont IL. β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects. Pathogens 2021;10:1638. [PMID: 34959593 DOI: 10.3390/pathogens10121638] [Reference Citation Analysis]
5 Fischer S, Klockgether J, Gonzalez Sorribes M, Dorda M, Wiehlmann L, Tümmler B. Sequence diversity of the Pseudomonas aeruginosa population in loci that undergo microevolution in cystic fibrosis airways. Access Microbiol 2021;3:000286. [PMID: 35024551 DOI: 10.1099/acmi.0.000286] [Reference Citation Analysis]